For the millions of Americans seeking addiction treatment for opioid use disorder, this development may be a gamechanger. Drugs have always posed a core contradiction. Opioids are effective pain relievers, but they can lead to addictions that devastate and claim lives.
For those with opioid addictions, a wide range of effective treatment options are available, from inpatient residential care to outpatient clinics. We’ve made it easy to get started in finding the right treatment program that fits your needs.
DFNZ Differs From Other Opioids
Most opioids cause euphoria by flooding the brain with dopamine, a neurochemical reward that reinforces repeated drug use and drives addiction. However, DFNZ didn’t produce a significant dopamine surge in animal testing. This key distinction may explain its apparently lower addictive profile.
The drug is derived from a class of compounds called nitazenes, which were developed in the 1950s and offered substantially more pain relief than morphine but carried a much higher overdose risk.
Researchers halted nitazene experiments and the compounds remained largely forgotten until they re-emerged as street drugs in recent years, according to NIDA pharmacologist Michael Michaelides.
As reported in the Rehab.com Addiction News Weekly Podcast, the new DFNZ compound was specifically engineered to retain pain-relief potency while reducing respiratory suppression and euphoria.
Dr. Sylvie Stacy, Chief Medical Officer at Rehab.com, noted that DFNZ features a “bouncer-like” mechanism that kicks the drug out of the brain before it has time to trigger a dopamine release. She explains that “by bypassing that spike, you can potentially provide significant pain relief without the euphoric reward that leads to drug misuse.”
Testing Addiction Potential
Research has broadly indicated that those dependent on prescription medications might find relief for chronic pain with a much lower risk of addiction. As Dr. Stacy points out, drug dependency doesn’t necessarily mean addiction.
“Dependence means their bodies have adapted to the medication,” Dr. Stacy said. “So if they stop suddenly, they have this fairly predictable and uncomfortable withdrawal syndrome.”
Here’s where the DFNZ can come into play. Researchers allowed rats to self-administer DFNZ via a lever-operated catheter, alongside another with morphine for comparison. When access was cut off, rats withdrawn from DFNZ gave up drug-seeking behavior faster than those taking morphine.
Those withdrawn from morphine showed severe withdrawal, including teeth chattering, jumping and paw tremors. They also kept pressing the now-inactive lever far more persistently, hoping to get high.
That pattern suggests DFNZ may be less reinforcing than morphine. But outside expert Natashia Swalve, an assistant professor of behavioral neuroscience at Grand Valley State University, observed that the self-administration data still indicates the potential for addiction.
DFNZ as an Addiction Treatment Option
In a separate phase of the study, researchers tested whether DFNZ could reduce heroin-seeking behavior in rats. Animals treated with DFNZ pressed a heroin-dispensing lever significantly less than those given a placebo.
That finding raised an intriguing possibility. Michaelides suggested, “DFNZ could potentially be used for the treatment of opioid use disorder similar to how methadone or buprenorphine are used.”
This can be a lifesaver for those undergoing drug and alcohol detox, but Michaelides stressed that multi-phase clinical trials would first need to demonstrate safety and efficacy. Dr. Stacy also cautioned, “We have to remember, of course, that a rodent’s brain and a human’s brain are not the same thing.”
Medications like buprenorphine are already central to medication-assisted treatment (MAT), the evidence-based standard of care for opioid use disorder. If DFNZ eventually clears clinical trials, it could represent a new addition to that toolkit, one potentially better suited to patients who develop dependencies following surgery or cancer treatment.
More Studies Warranted
The study has meaningful limitations. The team didn’t examine how the presence of ongoing pain might affect DFNZ’s addictive potential. This is a critical gap given the drug’s intended use in chronic pain conditions like cancer or post-surgical recovery. Researchers only tested a pain-relieving dose. They didn’t evaluate higher doses, which real-world patients sometimes take beyond their prescriptions.
Given the number of remaining safety tests and clinical trials ahead, independent experts estimate that clinical use for DFNZ might take at least a decade.
This research also doesn’t change current addiction treatment options, and DFNZ isn’t available outside of laboratory settings. For people currently navigating opioid use disorder, FDA-approved buprenorphine and methadone remain the standard of care.
Finding the Right Rehab
Research like this reinforces that addiction treatment is a rapidly evolving field. This can open up options when selecting a rehab center with clinically current approaches. When evaluating addiction treatment options, consider whether a facility offers medication-assisted treatment, what kinds of behavioral therapies are offered and how the facility approaches long-term recovery support.
The Rehab.com treatment provider directory includes thousands of verified treatment centers across the country. Or, call
800-985-8516
( 
Sponsored Helpline )
to speak with a treatment advisor who can help match you with centers that fit your clinical needs and circumstances.
